

10210 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

Honorable Gaylord Nelson

-5-


February 25, 1974

I commented in detail concerning the four articles appearing on their list which are recognized in the current National Formulary. Consequently, I will not repeat those comments here. Moreover, following my testimony, Dr. Daniel Banes testified on behalf of the USP, and during his appearance before the Subcommittee Dr. Banes offered his views relative to comparing the DPSC "additional requirements" with the specifications in the current USP. Hence, I also will not comment here on the so-called additional DPSC specifications for the USP articles.

* * * * *

I trust that the above comments will provide you with the analysis and evaluation desired by the Subcommittee. If I can be of any further assistance, or if you desire clarification relative to any of my comments, I shall be happy to cooperate.

Sincerely,



Edward G. Feldmann, Ph.D.
Associate Executive Director
for Scientific Affairs

ehb